Tyme Technologies Inc. (TYME)

[mcsharkey]

For next Tuesday's Investors Meeting and Proxy Vote, I'm asking for clarification on several topics.
Has our collaboration with LineaRX/APDN for molecular detection of invasive Circulating Tumor Cells (iCTCs) been replaced by our bio-marker collaboration with Evotec?
As of Evotec's own investors' meeting there is no mention of us within their meeting's video stream, or on their presentation @https://www.evotec.com/en/innovate/pharma-partnerships.

NCT03512756 - TYME's self-sponsored clinical trial with some collaboration with LINeaRX and Eagle Pharma, from milestones graphic below updates are due now-> end of September (1H22). To summarize, data listed on the Clinical Trial site was Last Update Posted : June 21, 2021. In our collaboration with Eagle RX:
Jan 7, 2020 Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration
///////OUR MILESTONE PAYMENT CAVEATS\\\\\\\\\\\\\
In addition, TYME will receive a $20 million MILESTONE payment upon the successful completion of the first to occur of the following three events:
(1) Achievement of the primary endpoint of overall survival in its TYME-88-Panc pivotal trial;
.....or
(2) Achievement of the primary endpoint of overall survival in the PanCAN Precision Promise? SM-88 registration arm;
.....or
(3) U.S. Food and Drug Administration (FDA) approval of SM-88 in any cancer.

This payment would be split into a $10 million milestone cash payment and a $10 million investment in TYME at a 15% premium to the then prevailing market price. Eagle’s shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement.
Hoping the trial status and working collaborations be fully discussed. If our therapeutics (i.e. SM-88, SM-18, et al) are now being manufactured by EVOTEC, please expound. Updates on our working agreements with EAGLE and LinEARX also requested.

Also from the milestone schedule:
NCT04720664-OASIS_Breast_Cancer, Last Update Posted : May 27, 2021, from the graphic: First Patient Enrolled 3Q21 (Oct -Dec 2020) is well passed.
We are currently nearing the end of 1H22. Reporting on our current NCT03778996 - Joseph Ahmed Foundation trial.
VR